SPRO Spero Therapeutics, Inc. Stock Quote

SPRO [NASD]

Index	-	P/E	-	EPS (ttm)	-3.48	Insider Own	16.03%	Shs Outstand	32.98M	Perf Week	62.46%
Market Cap	52.52M	Forward P/E	-	EPS next Y	-1.33	Insider Trans	1.86%	Shs Float	29.81M	Perf Month	74.24%
Income	-113.30M	PEG	-	EPS next Q	-0.25	Inst Own	59.40%	Short Float	1.38%	Perf Quarter	14.40%
Sales	9.90M	P/S	5.31	EPS this Y	17.50%	Inst Trans	3.23%	Short Ratio	0.17	Perf Half Y	-83.64%
Book/sh	1.09	P/B	1.31	EPS next Y	34.10%	ROA	-86.30%	Target Price	9.75	Perf Year	-92.11%
Cash/sh	1.24	P/C	1.16	EPS next 5Y	36.90%	ROE	-151.80%	52W Range	0.68 - 19.87	Perf YTD	-91.07%
Dividend	-	P/FCF	-	EPS past 5Y	-6.20%	ROI	-64.40%	52W High	-93.86%	Beta	1.87
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	122.50%	Gross Margin	-	52W Low	79.39%	ATR	0.18
Employees	41	Current Ratio	3.70	Sales Q/Q	-60.80%	Oper. Margin	-	RSI (14)	60.84	Volatility	40.29% 18.71%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-39.00%	Profit Margin	-	Rel Volume	10.20	Prev Close	1.43
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 AMC	Payout	-	Avg Volume	2.46M	Price	1.22
Recom	2.50	SMA20	30.69%	SMA50	45.84%	SMA200	-80.81%	Volume	4,069,068	Change	-14.69%

Oct-01-21

Downgrade

Oppenheimer

Outperform → Perform

Jan-22-21

Reiterated

H.C. Wainwright

Buy

$33 → $40

Dec-16-20

Initiated

Berenberg

Buy

$47

Sep-29-20

Initiated

Evercore ISI

Outperform

Nov-05-19

Reiterated

H.C. Wainwright

Buy

$28 → $35

Sep-09-19

Initiated

Janney

Buy

Feb-09-18

Initiated

Cantor Fitzgerald

Overweight

$27

Nov-27-17

Initiated

Stifel

Buy

$26

Nov-27-17

Initiated

Oppenheimer

Outperform

$30

Nov-27-17

Initiated

BofA/Merrill

Neutral

$16

Sep-07-22 12:37PM	Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More Zacks +26.55%
10:36AM	Spero (SPRO) Up Following Positive FDA Update for UTI Drug Zacks
08:05AM	Spero Therapeutics to Present at Upcoming Investor Conference GlobeNewswire
Sep-06-22 10:10AM	Spero Therapeutics Shares Jump After Upbeat FDA Feedback For Tebipenem HBr Program Benzinga +55.50%
08:05AM	Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration GlobeNewswire
Sep-05-22 06:49AM	Can Spero Therapeutics (NASDAQ:SPRO) Afford To Invest In Growth? Simply Wall St.
Aug-25-22 09:55AM	Spero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks +8.00%
Aug-10-22 05:25PM	Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates Zacks +9.51%
04:05PM	Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update GlobeNewswire
Aug-09-22 08:05AM	Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022 GlobeNewswire -5.42%
Jul-06-22 02:30AM	The Women Who Shaped Short-Term Rental History Skift
Jun-27-22 04:27PM	UPDATE 1-U.S. FDA declines to approve Spero's urinary tract infection drug Reuters
04:05PM	Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application GlobeNewswire
May-31-22 07:30AM	History of Short-Term Rentals Filled With Arrogance and Missed Opportunities Skift
May-16-22 05:35PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:05PM	Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update GlobeNewswire
May-11-22 08:05AM	Spero Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-09-22 08:05AM	Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022 GlobeNewswire -8.70%
May-04-22 09:15AM	Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.41%
May-03-22 05:29PM	Top 10 Losers on Tuesday Insider Monkey -63.65%
12:41PM	Spero lays off 110, looks to kill UTI drug American City Business Journals
09:59AM	FDA Identifies Review Issues For Spero's Tebipenem Application, Shares Plunge Benzinga
08:23AM	Spero Therapeutics stock plummets after biotech to cut 75% of its workforce MarketWatch
07:05AM	Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline GlobeNewswire
Apr-28-22 03:02PM	Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q1 Earnings Expected to Decline Zacks
Apr-21-22 08:05AM	Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases GlobeNewswire -7.29%
Apr-06-22 05:31PM	Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine GlobeNewswire
Mar-31-22 05:55PM	Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update GlobeNewswire
Mar-29-22 10:39AM	Is a Surprise Coming for Spero Therapeutics (SPRO) This Earnings Season? Zacks
Mar-28-22 06:51PM	We're Not Very Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate Simply Wall St.
Mar-17-22 08:05AM	Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022 GlobeNewswire
Feb-16-22 08:05AM	Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting GlobeNewswire
Feb-10-22 10:47AM	The past year for Spero Therapeutics (NASDAQ:SPRO) investors has not been profitable Simply Wall St.
Jan-20-22 05:36AM	The Petri Dish: Thermo Fisher taps Olaris, bluebird drugs delayed American City Business Journals
Jan-19-22 08:05AM	Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients GlobeNewswire
Jan-04-22 11:38AM	FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection Program Benzinga
08:48AM	Spero (SPRO) Application for UTI Drug Gets Priority Review Zacks
08:05AM	Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720 GlobeNewswire
Jan-03-22 08:05AM	Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis GlobeNewswire -5.37%
05:03AM	Spero Therapeutics Urinary-Tract Drug Gets FDA Priority Review TheStreet.com
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc GuruFocus.com
Nov-17-21 08:05AM	Spero Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-12-21 11:06AM	What Type Of Shareholders Make Up Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Registry? Simply Wall St.
Nov-10-21 05:45PM	Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update GlobeNewswire
Nov-03-21 08:05AM	Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021 GlobeNewswire
Oct-28-21 03:05PM	Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks +7.28%
08:05AM	Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis GlobeNewswire
Oct-12-21 08:05AM	Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors GlobeNewswire
Oct-05-21 07:11AM	3 Stocks Insiders Are Buying Benzinga
Oct-01-21 04:01PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-30-21 03:00PM	Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners Benzinga
08:00AM	Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million GlobeNewswire
Sep-28-21 12:45PM	Companies Like Spero Therapeutics (NASDAQ:SPRO) Are In A Position To Invest In Growth Simply Wall St.
Sep-16-21 08:05AM	Spero Therapeutics to Present Data at IDWeek 2021 GlobeNewswire
Sep-07-21 08:05AM	Spero Therapeutics to Present at Three Upcoming Investor Conferences GlobeNewswire
Sep-02-21 08:46AM	4 Stocks Insiders Are Buying Benzinga +5.78%
Aug-31-21 04:25PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.65%
12:00PM	Here's Why Momentum Investors Will Love Spero Therapeutics, Inc. (SPRO) Zacks
Aug-11-21 02:07AM	Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why Simply Wall St.
Aug-10-21 06:47AM	Investing in Spero Therapeutics (NASDAQ:SPRO) three years ago would have delivered you a 28% gain Simply Wall St.
Aug-05-21 05:55PM	Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update GlobeNewswire
Jul-30-21 04:33PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-29-21 04:01PM	Spero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021 GlobeNewswire
03:05PM	Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-07-21 04:01PM	Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference GlobeNewswire
12:56PM	Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More Zacks
Jul-06-21 01:00PM	Pfizer, Spero Sign Licensing Deal for SPR206 in Ex-Asia, Ex-U.S. Regions; Street Says Hold SmarterAnalyst
Jul-05-21 06:04AM	Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories PR Newswire
Jul-02-21 04:01PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-01-21 01:12PM	Why Spero Therapeutics Stock Is Up 15% Today Motley Fool +17.41%
Jun-30-21 06:46PM	Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206 GlobeNewswire
Jun-15-21 04:01PM	Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206 GlobeNewswire
Jun-11-21 07:48AM	Spero Therapeutics, Inc. (NASDAQ:SPRO) Is Expected To Breakeven In The Near Future Simply Wall St.
Jun-07-21 01:41PM	10 Tax Tips for Airbnb, HomeAway & VRBO Vacation Rentals TheStreet.com +7.11%
May-28-21 05:35PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-17-21 04:01PM	Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206 GlobeNewswire
May-13-21 08:00AM	Spero Therapeutics to Participate at the Berenberg Conference USA GlobeNewswire
May-06-21 06:05PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update GlobeNewswire
02:30PM	Spero Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Apr-30-21 04:26PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-29-21 04:01PM	Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 GlobeNewswire
Mar-31-21 04:31PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +8.08%
Mar-11-21 05:45PM	Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates Zacks +6.86%
04:07PM	Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update GlobeNewswire
02:30PM	Spero Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-09-21 05:31AM	Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Mar-08-21 12:30PM	Will Spero Therapeutics, Inc. (SPRO) Report Negative Q4 Earnings? What You Should Know Zacks
Mar-03-21 08:30AM	Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021 GlobeNewswire
Feb-25-21 08:30AM	Spero Therapeutics to Present at Investor Conferences in March GlobeNewswire
Feb-05-21 08:00AM	Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial GlobeNewswire
Jan-29-21 05:17PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-26-21 07:00AM	Spero Therapeutics (SPRO) Sees Hammer Chart Pattern: Time to Buy? Zacks
Jan-21-21 08:00AM	Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr GlobeNewswire
Jan-08-21 06:21AM	Spero Therapeutics (NASDAQ:SPRO) Shareholders Booked A 87% Gain In The Last Year Simply Wall St.
Dec-17-20 08:00AM	Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer GlobeNewswire
Dec-16-20 08:30AM	Spero Therapeutics Added to the NASDAQ Biotechnology Index GlobeNewswire +5.52%

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shukla Sath	Chief Financial Officer	Aug 29	Sale	0.89	6,017	5,378	56,064	Aug 30 05:00 PM
Aquilo Capital Management, LLC	10% Owner	Apr 26	Buy	5.24	39,727	207,971	5,321,231	Apr 28 04:13 PM
Aquilo Capital Management, LLC	10% Owner	Mar 30	Buy	8.79	50,000	439,420	5,281,504	Mar 31 03:51 PM
Aquilo Capital Management, LLC	10% Owner	Mar 14	Buy	7.63	23,708	180,797	5,231,504	Mar 16 04:23 PM
Aquilo Capital Management, LLC	10% Owner	Feb 28	Buy	9.53	44,833	427,227	5,207,796	Mar 02 03:52 PM
Aquilo Capital Management, LLC	10% Owner	Feb 18	Buy	9.24	14,828	137,039	5,162,963	Feb 23 04:24 PM
Aquilo Capital Management, LLC	10% Owner	Jan 31	Buy	11.59	125,000	1,448,262	5,148,135	Feb 01 08:26 PM
Aquilo Capital Management, LLC	10% Owner	Jan 24	Buy	10.89	1,599	17,418	5,023,135	Jan 26 05:12 PM
Aquilo Capital Management, LLC	10% Owner	Jan 18	Buy	12.41	48,488	601,964	5,021,536	Jan 20 01:07 PM
Aquilo Capital Management, LLC	10% Owner	Jan 10	Buy	12.93	8,867	114,609	4,973,048	Jan 12 04:43 PM
Aquilo Capital Management, LLC	10% Owner	Dec 31	Buy	15.75	125,000	1,969,025	4,964,181	Jan 03 02:46 PM
Aquilo Capital Management, LLC	10% Owner	Dec 30	Buy	15.77	50,000	788,610	4,839,181	Jan 03 02:46 PM
Aquilo Capital Management, LLC	10% Owner	Dec 29	Buy	14.64	75,493	1,105,263	4,789,181	Jan 03 02:46 PM
Mahadevia Ankit	CEO and President	Dec 27	Option Exercise	5.90	8,000	47,200	152,036	Dec 29 06:26 PM
Mahadevia Ankit	CEO and President	Dec 27	Sale	14.58	8,000	116,666	144,036	Dec 29 06:26 PM
Aquilo Capital Management, LLC	10% Owner	Oct 29	Buy	17.53	150,000	2,630,175	4,713,688	Nov 02 05:47 PM
Aquilo Capital Management, LLC	10% Owner	Sep 30	Buy	18.65	134,543	2,509,173	4,563,688	Oct 04 11:36 AM
Aquilo Capital Management, LLC	10% Owner	Sep 14	Buy	18.49	2,156	39,872	4,429,145	Sep 15 07:21 PM
Aquilo Capital Management, LLC	10% Owner	Sep 13	Buy	18.56	44,210	820,675	4,426,989	Sep 15 07:21 PM
Aquilo Capital Management, LLC	10% Owner	Sep 09	Buy	18.50	24,749	457,792	4,382,779	Sep 10 05:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience